45m agoSeeking AlphaBULLISH 73Product/PR
Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment
Genmab and AbbVie’s Epkinly + R-CHOP cut progression/death risk 51% in phase 3 DLBCL trial vs R-CHOP alone. Read more here.
Why Is GENMAB A/S ADR (GMAB) Stock Up Today?
By the Top Tier Newswire AI Desk · reviewed against 13 wire stories
GENMAB A/S ADR (GMAB) is up +10.73% in the latest session. Our newswire has captured 13 stories on GMAB across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for GMAB publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
GMAB by the numbers
Last: $38.48Session: +10.73%7 sessions: +3.34%Coverage: 13 stories / 8 sourcesAI sentiment: 65/100 (bullish)
The headlines behind the move
1h agoInvesting.com MarketsBULLISH 73Product/PR
Genmab stock surges 11% on positive cancer drug trial data
Genmab stock surges 11% on positive cancer drug trial data
1h agoThe FlyBULLISH 67Product/PR
Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study
1h agoPR NewswireBULLISH 73Product/PR
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the...
1h agoGlobeNewswireBULLISH 73Product/PR
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and...
5h agoMarketChameleonNEUTRAL 50General
Genmab discloses Darwin Global stake at 5.11% of voting rights
Genmab disclosed that Darwin Global Management Limited controls voting rights attached to 3,188,361 shares—5.11% of Genmab’s voting rights—as of September 28, 2026. The announcement is a regulatory major-shareholder notice rather than a business or pipeline update, with GMAB trading at $35.70 as of 11:04 AM.
9h agoThe FlyBULLISH 67Analyst
Genmab price target raised to $54 from $45 at Guggenheim
9h agoInvesting.com Analyst RatingsBULLISH 61Analyst
Guggenheim raises Genmab stock price target on pipeline potential
Guggenheim raises Genmab stock price target on pipeline potential
9h agoMarketChameleonBULLISH 67Product/PR
Genmab Highlights Rina-S Responses in Platinum-Resistant Ovarian Cancer, with 51% of Responders Still in Response at One Year October 5, 2026
Genmab reported Phase 1/2 RAINFOL-01 Part C results showing a confirmed 45.9% objective response rate for investigational ADC Rina-S in 109 patients with platinum-resistant ovarian cancer, with a 12.1-month median duration of response and 51% of responders still in response at one year. The company also reported a 9.5-month median progression-free survival and said activity was observed regardless of FRa expression level, including low and non-expressors, as multiple Phase 3 trials continue.
11h agoInvesting.com MarketsNEUTRAL 50General
Why is Genmab stock rallying today?
Why is Genmab stock rallying today?
Frequently asked questions
Why is GMAB stock up today?
GENMAB A/S ADR (GMAB) is up +10.73% in the latest session. Our newswire has captured 13 stories on GMAB across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100). The most recent driver: "Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment" (Seeking Alpha).
Is GMAB a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of GMAB coverage reads 65/100 over 13 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is PTC up today (+33.49%)
- Why is PCVX up today (+31.01%)
- Why is XP up today (+30.93%)
- Why is RXO up today (+22.54%)
- Why is PAGS up today (+21.40%)
- Why is STNE up today (+20.84%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on GMAB: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.